GRFS
Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 6.93$. Average daily volumn in 3 months 1.47M. Market cap 6.53B
Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD Lastest price : 8.05$. Total volume : 658.66k. Market state POST Click reload if you want to check the lastest price on market!!!
Grifols, S.A. (GRFS)
Last Price
8.05$Change
-0.42Volume
658.66k
| Previous Close | 8.47 |
| Open | 8.21 |
| Day Range | 8.03-8.28 |
| Bid | 8.00 x 1.8k |
| Ask | 10.00 x 1k |
| Volume | 658.66k |
| Average Volume | 1.47M |
| Market Cap | 6.53B |
| Beta | 0.44 |
| 52 Week Range | 5.71-13.34 |
| Trailing P/E | 73.18 |
| Foward P/E | 15.78 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | 2021-06-03 |
Financial Details
Organization
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumยfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringยto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Market Cap:
6.53BRevenue:
4.93BTotal Assets:
19.23BTotal Cash:
655.49M
News about "Grifols, S.A."
GRLS.MC - Grifols SA | Stock Price & Latest News | Reuters
Source from : Reuters - 9 days ago
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes ...See details»
Grifols S.A. ADR
Source from : Wall Street Journal - 6 days ago
1 Day GIKLY 5.20% DJIA 2.18% S&P 500 3.09% Health Care/Life Sciences -0.45% Raimon Grifols Roura Joint Chief Executive Officer & Executive Director Grifols Escrow Issuer SA, Grifols SA, Grifols ...See details»
Grifols SA - ADR - Level III
Source from : U.S. News & World Report - 8 days ago
Financial advisors can help clients navigate an inheritance by following these best practices.See details»
Grifols S.A. reports Q3 results
Source from : Seeking Alpha - 26 days ago
To ensure this doesnโt happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»
GRFS Grifols, S.A.
Source from : Seeking Alpha - 14 days ago
To ensure this doesnโt happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»
Grifols receives FDA clearance for AlphaIDโข At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Source from : Benzinga.com - 1 month ago
Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»
Grifols SA PRF UNDATED EUR 0.05
Source from : Morningstar%2c Inc. - 12 days ago
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do ...See details»
Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS)
Source from : The Globe and Mail - 5 month ago
Kepler Capital analyst Dariusz Ubik maintained a Hold rating on Grifols SA (GRFS โ Research Report) on July 1 and set a price target of EUR22.90. The companys shares closed last Friday at $12.49.See details»
Spanish pharmaceuticals firm Grifols reports 30% drop in nine-month profit
Source from : Reuters - 28 days ago
The logo of the Spanish pharmaceuticals company Grifols is pictured on their headquarters' building in Sant Cugat del Valles, near Barcelona, Spain, September 17, 2021. REUTERS/Albert Gea MADRID ...See details»
Plasma Fractionation Technology Market Outlook 2022 and Forecast to 2028 |CSL, Grifols,S.A, Takeda Pharmaceutical
Source from : MarketWatch - 13 days ago
The MarketWatch News Department was not involved in the creation of this content. Nov 24, 2022 (Heraldkeepers) -- Plasma Fractionation Technology Market report analyses top opportunities in the market ...See details»
Grifols opens new medical protein purification plant in Dublin
Source from : The Irish Times - 1 month ago
Spanish pharma group Grifols has opened a large new extension at its Dublin site. The new albumin purification plant marks a significant upgrade for the Irish operation, which started life as a ...See details»
Teams in Playoff Contention | Good Side Presented by Grifols Plasma Donation Centers
Source from : NFL - 5 days ago
Daniel Jeremiah and Bucky Brooks are back with a new episode of Move the Sticks. The guys are joined by 7-time Pro Bowl LB Luke Kuechly throughout the show. The group hit on a variety of topics ...See details»
Grifols says U.S. blood donors' lawsuit won't have material impact, shares down
Source from : Yahoo Finance - 1 month ago
MADRID (Reuters) - Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a ...See details»
Grifols receives FDA clearance for AlphaID(TM) At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Source from : MarketWatch - 1 month ago
Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»